BlackRock
TARS icon

BlackRock’s Tarsus Pharmaceuticals TARS Stock Holding History

BlackRock’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$243M Buy
3,856,137
+303,525
+9% +$19.4M ﹤0.01% 1677
2026
Q1 		$249M Sell
3,552,612
-237,945
-6% -$16.6M ﹤0.01% 1534
2025
Q4 		$310M Buy
3,790,557
+10,936
+0.3% +$817K 0.01% 1406
2025
Q3 		$225M Sell
3,779,621
-12,564
-0.3% -$619K ﹤0.01% 1603
2025
Q2 		$154M Buy
3,792,185
+638,457
+20% +$28.7M ﹤0.01% 1778
2025
Q1 		$162M Sell
3,153,728
-385,117
-11% -$19M ﹤0.01% 1715
2024
Q4 		$196M Sell
3,538,845
-216,659
-6% -$9.84M ﹤0.01% 1681
2024
Q3 		$124M Buy
3,755,504
+488,790
+15% +$13.7M ﹤0.01% 1962
2024
Q2 		$88.8M Buy
3,266,714
+614,034
+23% +$20.6M ﹤0.01% 2094
2024
Q1 		$96.4M Buy
2,652,680
+136,541
+5% +$4.01M ﹤0.01% 2065
2023
Q4 		$51M Buy
2,516,139
+305,816
+14% +$5.11M ﹤0.01% 2457
2023
Q3 		$39.3M Buy
2,210,323
+10,570
+0.5% +$187K ﹤0.01% 2543
2023
Q2 		$39.7M Buy
2,199,753
+742,493
+51% +$11.8M ﹤0.01% 2633
2023
Q1 		$18.3M Buy
1,457,260
+116,001
+9% +$1.7M ﹤0.01% 3023
2022
Q4 		$19.7M Buy
1,341,259
+222,498
+20% +$3.68M ﹤0.01% 3049
2022
Q3 		$19.2M Buy
1,118,761
+103,128
+10% +$1.64M ﹤0.01% 3055
2022
Q2 		$14.8M Buy
1,015,633
+575,675
+131% +$8.64M ﹤0.01% 3262
2022
Q1 		$7.4M Sell
439,958
-9,000
-2% -$167K ﹤0.01% 3741
2021
Q4 		$10.1M Buy
448,958
+7,338
+2% +$191K ﹤0.01% 3666
2021
Q3 		$9.52M Buy
441,620
+3,264
+0.7% +$80.8K ﹤0.01% 3696
2021
Q2 		$12.7M Buy
438,356
+98,559
+29% +$3.08M ﹤0.01% 3557
2021
Q1 		$11M Buy
339,797
+17,374
+5% +$642K ﹤0.01% 3511
2020
Q4 		$13.3M Buy
+322,423
New +$9.18M ﹤0.01% 3222

Other funds holding TARS

DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

BlackRock's TARS Position: Q2 2026 in Review

BlackRock increased its Tarsus Pharmaceuticals (TARS) stake by 8.5% in Q2 2026, buying an estimated $19.4M and bringing the position to 3,856,137 shares worth $243M. The position accounts for ﹤0.01% of the portfolio, ranked #1677.

BlackRock first reported a position in TARS in Q4 2020 and has held it in 23 quarters since. The position peaked at $310M in Q4 2025. 257 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

  • BlackRock held 3,856,137 shares of Tarsus Pharmaceuticals worth $243M as of Q2 2026.
  • BlackRock bought 303,525 Tarsus Pharmaceuticals shares in Q2 2026, an estimated $19.4M.
  • Tarsus Pharmaceuticals made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #1677 holding.
  • BlackRock first reported a position in Tarsus Pharmaceuticals in Q4 2020 and has held it in 23 quarters since.
  • BlackRock's Tarsus Pharmaceuticals position peaked at $310M in Q4 2025.
  • 257 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.